@article {Kazmer2021.12.22.21268265, author = {Seth T. Kazmer and Gunter Hartel and Harley Robinson and Renee S. Richards and Kexin Yan and Sebastiaan J. Van Hal and Raymond Chan and Andrew Hind and David Bradley and Fabian Zieschang and Daniel J. Rawle and Thuy T. Le and David W. Reid and Andreas Suhrbier and Michelle M Hill}, title = {Infrared spectroscopy enables rapid, robust, portable COVID-19 saliva screening based on pathophysiological response to SARS-CoV-2}, elocation-id = {2021.12.22.21268265}, year = {2021}, doi = {10.1101/2021.12.22.21268265}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Fourier-transform infrared (FTIR) spectroscopy provides a (bio)chemical snapshot of the sample, and was recently proposed for COVID-19 saliva screening in proof-of-concept cohort studies. As a step towards translation of this technology, we conducted controlled validation experiments in multiple biological systems. SARS-CoV-2 or UV-inactivated SARS-CoV-2 were used to infect Vero E6 cells in vitro, and K18-hACE2 mice in vivo. Potentially infectious culture supernatant or mouse oral lavage samples were treated with ethanol or Trizol to 75\% (v/v) for attenuated total reflectance (ATR)-FTIR spectroscopy, or RT-PCR, respectively. The control condition, UV-inactivated SARS-CoV-2 elicited strong biochemical changes in culture supernatant/oral lavage despite lack of replication determined by RT-PCR or cell culture infectious dose 50\%. Crucially, we show that active SARS-CoV-2 infection induced additional FTIR signals over the UV-inactivated SARS-CoV-2 infection, which correspond to innate immune response, aggregated proteins, and RNA. For human patient cohort prediction, we achieved high sensitivity of 93.48\% on leave-on-out cross validation (n=104 participants) for predicting COVID-19 positivity using a partial least squares discriminant analysis model, in agreement with recent studies. However, COVID-19 patients negative on follow-up (RT-PCR on day of saliva sampling) were poorly predicted in this model. Importantly, COVID-19 vaccination did not lead to mis-classification of COVID-19 negatives. Meta-analysis revealed SARS-CoV-2 induced increase in Amide II band in all arms of this study and recent studies, indicative of altered β-sheet structures in secreted proteins. In conclusion, ATR-FTIR is a robust, simple, portable method for COVID-19 saliva screening based on detection of pathophysiological responses to SARS-CoV-2.Competing Interest StatementAH, DB, FZ are employees of Agilent Technologies. All other authors declare that they have no competing interests.Funding StatementThis project was supported by Agilent Technologies Applications \& Core Technology - University Research Grant (MMH), QIMR Berghofer Medical Research Institute COVID Research (AS, DR) and The Prince Charles Hospital Research Foundation (DR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human research ethics committee of QIMR Berghofer Medical Research Institute gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw FTIR spectra and associated clinical data are available at DOI: 10.5281/zenodo.5703689, Proteomics data are available via ProteomeXchange with identifier PXD030012. https://zenodo.org/record/5703689$\#$.YZLxWGBBxaQ}, URL = {https://www.medrxiv.org/content/early/2021/12/24/2021.12.22.21268265}, eprint = {https://www.medrxiv.org/content/early/2021/12/24/2021.12.22.21268265.full.pdf}, journal = {medRxiv} }